Johnson & Johnson stock ends the week at EUR 233.40 with psoriasis data
Published on 10/10/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Johnson & Johnson was last quoted at EUR 233.40 on October 9, 2026.
- Lang & Schwarz cited EUR 227.50 as the prior close on October 8, 2026.
- Johnson & Johnson reported two-year ICOTYDE psoriasis data from the ICONIC-LEAD study.
Johnson & Johnson stock was last quoted at EUR 233.40 by Lang & Schwarz at 10:00 p.m. CEST on October 9, 2026, versus EUR 227.50, the prior close at Lang & Schwarz on October 8, 2026. On October 9, Johnson & Johnson reported new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE in adults and adolescents with moderate-to-severe plaque psoriasis, according to the company’s press release.
Market context: Market report S&P 500.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.
The week in figures
The recorded Lang & Schwarz quote was EUR 233.40 on October 9, 2026, compared with EUR 227.50 on October 8, 2026. The quote page reported an increase of 2.59 percent between those reference prices. The figures are euro quotations for the German trading venue and are separate from Johnson & Johnson’s primary U.S. listing.
Chronology of the week
On October 9, Johnson & Johnson reported that at least 72 percent of ICOTYDE-treated patients achieved a PASI 90 score and at least 70 percent achieved clear or almost clear skin from Week 64 through Week 112. The company said the ICONIC-LEAD study enrolled 684 participants, including 66 adolescents. The company also reported that safety findings through Week 112 remained consistent with the established safety profile.
Dates of the coming week
Johnson & Johnson’s next results date is listed as October 13, 2026, according to Stock Analysis.
